Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 2/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.36 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.36 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.36 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.36 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.36 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4063393 | 0.89 | MKNK1 (0.39) | CACNA1HCACNA1GCYP2C8CYP2C9NPC1 | |
| SCHEMBL4058483 | 0.88 | CYP11B1 (0.41) | NPC1LMNAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL4051786 | 0.88 | P2RY14 (0.43) | CYP2C8CYP2C9CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4061552 | 0.88 | NOS3 (0.41) | CYP2C8CYP2C9NPC1LMNAMAPT | |
| SCHEMBL4056967 | 0.85 | SMN1; SMN2 (0.39) | CYP2C8CYP2C9NPC1LMNAMAPT | |
| SCHEMBL13607986 | 0.84 | KIT (0.45) | KITFFAR1CYP2C8CYP2C9CYP1A1 | |
| SCHEMBL4054960 | 0.84 | MAPT (0.36) | CYP2C8CYP2C9NPC1LMNAMAPT | |
| SCHEMBL4060275 | 0.83 | ADRA2A (0.36) | CYP2C8CYP2C9NPC1LMNAMAPT | |
| SCHEMBL4060685 | 0.82 | KIT (0.42) | KITCACNA1HCACNA1GTRPV1PRMT5 | |
| SCHEMBL4051006 | 0.82 | RIPK1 (0.46) | NPC1LMNAMAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622479-B2 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20050101647-A1 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1460067-A1 | BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101647-A1 | Bicyclic derivative, its production and use | ABL1, SRC, PTK2B | KIT 493/4885FFAR1 3632/4885CACNA1H 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.